Featured Research

from universities, journals, and other organizations

New treatment to overpower drug resistance in ovarian cancer

Date:
November 15, 2010
Source:
Centenary Institute
Summary:
A new treatment kills ovarian cancer cells in a way that can break the resistance mechanism -- even in those resistant to cisplatin. Researchers found the drug (FTY720) had a potent effect in human ovarian cancer cells, even in those resistant to cisplatin, the most commonly used chemotherapeutic drug currently available for the treatment of ovarian cancer.

New research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a way that can break the resistance mechanism -- even in those resistant to cisplatin.

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism. Published in Autophagy, the researchers found the drug (FTY720) had a potent effect in human ovarian cancer cells, even in those resistant to cisplatin, the most commonly used chemotherapeutic drug currently available for the treatment of ovarian cancer.

Centenary Institute Signal Transduction Head Associate Professor Pu Xia described the findings as a breakthrough in ovarian cancer treatment because, FTY720 kills ovarian cancer cells through a unique way different to the current anti-cancer drugs. Current treatments, such as cisplatin, kill ovarian cancer cells through a way of programming cell death known as apoptosis but this is often reversible or demolished by cancer cells. However, FTY720 kills cells through an irreversible process known as necrosis so the cancer cells cannot resist, repair and relapse.

Ovarian cancer is the leading cause of death in women with gynaecological malignancies in the world.

Dr Xia said: "One of the major reasons for such a poor outcome of ovarian cancer is that the cancer cells have an ability to resist the current chemotherapeutic drugs through a protective shield, which occurs naturally or as a response to the treatment, and this survives the cancer from the treatment. Such a protective shield, uncovered by the findings from the Xia laboratory, is built, at least partially, on a catabolic process, called autophagy, by which cells eat their own non-vital components for survival under stress conditions such as starvation or chemotherapy. Remarkably, despite this survival process being activated by ovarian cancer cells during the treatment, FTY720 is still capable of killing them effectively.

While this research is a major first step toward developing a more effective treatment for ovarian cancer, the researchers claim more pre-clinical and clinical trials are needed before the drug might be used in women with ovarian cancer. However, the researchers are optimistic that the treatment would be available as a new chemotherapeutic agent within the next several years, because this drug has been approved by the US Food and Drug Administration (FDA) for use in the treatment of multiple sclerosis and is also used in multiple clinical trials for the prevention of organ transplant rejection and the treatment of various autoimmune diseases. Recent studies have also shown anti-tumour efficacy in several types of cancers but this is the first time it has been studied for the treatment of ovarian cancer.

This research was made possible by a Research Fellowship from the Cancer Institute New South Wales to Associate Professor Xia. The project also received support from the National Health and Medical Research Council and Science and Technology Council of Shanghai Municipality.


Story Source:

The above story is based on materials provided by Centenary Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ning Zhang, Yanfei Qi, Carol Wadham, Lijun Wang, Alessandra Warren, Wen Di, Pu Xia. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: A protective role of autophagy. Autophagy, 2010; 6 (8): 1157 DOI: 10.4161/auto.6.8.13614

Cite This Page:

Centenary Institute. "New treatment to overpower drug resistance in ovarian cancer." ScienceDaily. ScienceDaily, 15 November 2010. <www.sciencedaily.com/releases/2010/11/101115101137.htm>.
Centenary Institute. (2010, November 15). New treatment to overpower drug resistance in ovarian cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/11/101115101137.htm
Centenary Institute. "New treatment to overpower drug resistance in ovarian cancer." ScienceDaily. www.sciencedaily.com/releases/2010/11/101115101137.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins